Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial.

Keywords: dipeptidyl peptidase-4 inhibitor; evogliptin; magnetic resonance imaging-derived proton density fat fraction; non-alcoholic fatty liver disease; pioglitazone; type 2 diabetes EN dipeptidyl peptidase-4 inhibitor evogliptin magnetic resonance imaging-derived proton density fat fraction non-alcoholic fatty liver disease pioglitazone type 2 diabetes 752 756 5 03/11/22 20220401 NES 220401 PEER REVIEW The peer review history for this article is available at https://publons.com/publon/10.1111/dom.14623. Effects on fatty liver-related variables Changes in fatty liver-related variables following 24 weeks of treatment compared with baseline are presented in Table S1. Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial In this study, we performed a head-to-head comparison of the efficacy and safety of evogliptin versus pioglitazone for treating patients with T2D complicated by NAFLD in decreasing fatty liver burden. [Extracted from the article]